TargetMol se distingue parmi les marques de nos partenaires, qui sont plus de 25

NPC 567 is an antagonist of the bradykinin receptor.

NBTI 5463 is a bacterial type II topoisomerase (topoisomerase II) inhibitor with antimicrobial properties. It effectively inhibits GyrA and TopoIV in Pseudomonas aeruginosa and Escherichia coli. By binding to topoisomerase II, NBTI 5463 prevents DNA cleavage and re-ligation, thereby impeding bacterial DNA replication and transcription. This compound shows potential for research into Gram-negative bacterial infections.

NAPAP is a thrombin inhibitor with potent anticoagulant activity (Ki: 2.1 nM). It selectively inhibits thrombin through a rapid binding mechanism while exhibiting weaker inhibition of trypsin, Factor Xa, and plasmin. NAPAP can be utilized for research into thrombotic conditions, including venous thrombosis and myocardial infarction.

NPC 567 acetate is a bradykinin B2 antagonist and can be used in studies about the treatment of allergic airway disease.

Deca-1,5,9-triene is a biochemical.

Mpro/Cathepsin L-IN-2 (Compound 1) is an irreversible dual inhibitor targeting the main protease of SARS-CoV-2 (Mpro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 shows potential for use in research related to COVID-19 and other coronavirus infections.

BER-5 is a potent MrgX2 antagonist, demonstrating broad-spectrum antagonistic activity against various MrgX2 agonists. It can inhibit Substance P(SP)-induced degranulation in LAD2 cells and alleviate SP-induced allergic reactions in mice. BER-5 is useful for researching mechanisms related to allergic reactions.

TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.

PROTACBRD4 Degrader-33 is an enzyme-activated, click-responsive BRD4 PROTAC degrader designed with effective tumor microenvironment responsiveness. This compound exhibits exceptional penetration into tumor tissues and effectively inhibits PD-L1 protein expression. In the 4T1 tumor mouse model, PROTACBRD4 Degrader-33 demonstrates potent antitumor immunomodulatory activity.

CCC-0975 is an inhibitor of hepatitis B virus (HBV) with an EC50 of 10 μM. It interferes with the conversion of relaxed circular DNA (rcDNA) to covalently closed circular DNA (cccDNA) and reduces cccDNA and its precursor deproteinized rcDNA (DP-rcDNA), without promoting their degradation inside cells. CCC-0975 holds potential for chronic hepatitis B research.

Y040-7904 is a potential mitochondrial autophagy activator. It enhances mitochondrial autophagy by facilitating the transport of mitochondria to autophagosomes and promoting the fusion of autophagosomes with autolysosomes. Y040-7904 induces mitochondrial autophagy through the SIRT1/FoxO3 pathway and upregulates the levels of Parkin, PINK1, and LC3II/I. Additionally, Y040-7904 reduces Aβ accumulation in both in vitro and in vivo Alzheimer's disease models.

KDX1381 is a bivalent CK2α inhibitor with an IC50 of 17 nM and a KD of 54 nM. It demonstrates antitumor activity in murine 786-O and A375 xenograft models. Furthermore, when combined with a vascular endothelial growth factor receptor (VEGFR) inhibitor or DNA-damaging agents, KDX1381 enhances antitumor effects in mouse hepatocellular carcinoma and glioma models.

alpha-Artemether is a Quinghaosu derivative with antifungal and antimalarial activity.

F3-PEG8-RiboTAC is a RiboTAC compound that specifically degrades the mRNA of the oncogene LGALS1. This compound can induce apoptosis (cell death) in tumor cells and inhibit their invasion. F3-PEG8-RiboTAC exhibits antitumor activity and is applicable in research on leukemia and triple-negative breast cancer. (RNase L ligand; RNA binder; Linker)

<p>Artemisitene, an oxidized antimalarial derivative of Artemisinin, stems from precursors like Artemisinin B and Artemisinic acid.</p>

ZSH-2117 is a covalent and selective EGFR PROTAC degrader, with a DC50 of 45 nM in Ba/F3-EGFR[L858R/T790M/C797S] cells. It significantly inhibits cell proliferation and reduces AKT and ERK protein levels in downstream EGFR signaling pathways. ZSH-2117 effectively suppresses tumor growth in Ba/F3-EGFR[L858R/T790M/C797S] xenograft mouse models.

Norepinephrine bitartrate salt is an adrenergic neurotransmitter.

GLP-1R modulator-1 (Compound 384) is a potent and orally active selective agonist of the glucagon-like peptide-1 receptor (GLP-1R). It activates G protein-coupled signaling, leading to increased intracellular cAMP levels, enhanced insulin secretion, delayed gastric emptying, and reduced appetite. GLP-1R modulator-1 holds potential for research in type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

t9,t11,c15-CLNA is an isomer of conjugated linolenic acid (CLNA) produced by Lactobacillus plantarum ZS2058. It exhibits key activities including anti-inflammatory and antioxidant effects, as well as enhancement of intestinal barrier function. The regulatory mechanisms of t9,t11,c15-CLNA involve the upregulation of tight junction proteins, the inhibition of pro-inflammatory cytokines (such as TNF-α, IL-6), and the activation of antioxidant enzymes (such as SOD, CAT). t9,t11,c15-CLNA can be utilized in research on inflammatory bowel disease (like colitis).

PROTACsEH degrader-2 is a PROTAC degrader that targets soluble epoxide hydrolase (sEH), with pIC50 values of 8.37 (human sEH-H) and 7.12 (mouse sEH-H). It is applicable for research into inflammation and neuroinflammation-related diseases, such as Alzheimer's disease.